GlassScriptPhysician profile
Mirza B Baig
NPI 1497733018
$11,466.24
in general payments reported to CMS, 2019-2025
34 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,773 · 2020: $397 · 2021: $547 · 2022: $1,109 · 2023: $2,990 · 2024: $1,855 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335 · Travel and Lodging: $2,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.31 |
| Travel and Lodging | $2,305.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $3,580.81 | 2019-2024 | Zenith Alpha |
| Penumbra, INC. | $2,277.28 | 2019-2023 | Indigo System |
| Abbott Laboratories | $980.33 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $641.69 | 2019-2022 | |
| Boston Scientific Corporation | $519.57 | 2019-2025 | Bodyguardian, Avvigo Guidance System, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $497.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $371.72 | 2022-2025 | Verquvo |
| Amgen INC. | $335.05 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $252.15 | 2020-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.79 | 2022-2025 | Jardiance |
| Biotronik INC. | $195.84 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $179.24 | 2024 | Inpefa |
| Baxter Healthcare | $156.31 | 2020-2024 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $151.55 | 2025 | Heli-Fx Endoanchor System |
| Bolton Medical INC | $148.43 | 2023 | Relay Thoracic Stent-Graft With Plus Delivery System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $145.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $101.21 | 2019-2022 | |
| Irhythm Technologies, INC. | $93.18 | 2024 | Zio Monitor, Zio Xt Patch |
| Abiomed | $84.85 | 2025 | |
| Medinc of Texas | $71.11 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.41 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $65.64 | 2021-2025 | Eliquis |
| Amarin Pharma, INC. | $57.24 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $35.82 | 2019 | |
| Edwards Lifesciences Corporation | $32.64 | 2023 | Sapien 3 Ultra Resilia |
| Welch Allyn | $31.23 | 2019 | |
| Abbvie INC. | $27.67 | 2023 | Teflaro, Dalvance, Avycaz |
| Scpharmaceuticals INC. | $23.25 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.08 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $18.26 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.23 | 2025 | |
| Cagent Vascular INC | $15.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.77 | 2019 | |
| Si-Bone, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirza Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.